1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On April 21, 2026, Journey Medical Corporation said about 85% of US commercial lives now have access to Emrosi, its rosacea treatment, after contracting with a third major group purchasing organization. The company said commercial-life access rose from about 100 million to over 150 million as of April 1, 2026. Management expects wider coverage to support further prescription demand and, over time, less reliance on its co-pay bridging program and better brand profitability, but the filing reports no financial results.
Emrosi access now covers about 85% of US commercial lives after a contract with the third major GPO
Commercial lives with access rose from about 100 million to over 150 million as of April 1, 2026
Management expects less reliance on the co-pay bridging program and improved brand profitability as formulary adoption grows
Centrus Energy's subsidiary American Centrifuge Operating signed a construction contract dated April 16, 2026, with Geiger Brothers for its Piketon, Ohio uranium enrichment expansion. The contract is capped at $900 million, and the final cost will depend on the detailed work the company authorizes, so shareholders will see the actual spending as task releases are issued.
Contract dated April 16, 2026; Geiger Brothers is the primary construction contractor for the Piketon, Ohio expansion project.
Aggregate payments are capped at $900 million under a time and materials structure with agreed labor rates.
Performance period runs through January 30, 2031.
The company expects to file the full contract as an exhibit to its Form 10-Q for the quarter ending June 30, 2026.
BT Brands disclosed that its proposed merger partner, Aero Velocity Inc., has entered into a strategic partnership with AC Future, Inc. to jointly develop a Mobile Drone Launch Vehicle platform for U.S. military and public-sector applications. The filing reports no financial results, deal terms, or changes to the pending merger, which is expected to close in 2026 subject to stockholder approvals.
Partnership announced April 14, 2026 in conjunction with TEVCON in San Diego, California
Companies expect to pursue U.S. Department of War and other government funding opportunities
Pending merger with Aero Velocity expected to close in 2026, subject to stockholder approvals and customary conditions
Combined company expected to operate as Aero Velocity Inc. and trade on the Nasdaq Capital Market
MAIA Biotechnology said it activated its first U.S. clinical site, Summit Medical Group in New Jersey, for the expansion of its Phase 2 THIO-101 trial of ateganosine in third-line non-small cell lung cancer. The company plans four more U.S. sites in 2026, and the U.S. portion of third-line testing is funded by a $2.3 million NIH grant; the filing reports no financial results or guidance.
First U.S. site activated: Summit Medical Group in New Jersey, with principal investigator Charles J. Kim, M.D.
MAIA intends to open four additional U.S. sites in 2026.
U.S. third-line evaluation is funded by a $2.3 million grant from the National Institutes of Health.
Trial is ongoing in Europe and Asia with 44 active sites in 6 countries.
On April 13, 2026, the Trust entered into an amended and restated staking addendum to its Coinbase custody services agreement, filed as Exhibit 10.1. The filing does not disclose financial terms, and the schedules and exhibits were omitted under Regulation S-K, so the changes to custody and staking arrangements are not described in detail.
Agreement dated April 13, 2026: amended and restated staking addendum to the Coinbase Custody Custodial Services Agreement
Addendum relates to the Third Amended and Restated Coinbase Prime Broker Agreement dated May 21, 2024
Schedules and exhibits omitted under Item 601(a)(5) of Regulation S-K; Trust will furnish them to the SEC on request
Filing signed April 15, 2026 by Bryan Bowers, Director and CFO of iShares Delaware Trust Sponsor LLC
Xtant Medical entered a distribution agreement dated April 10, 2026 with Dilon Technologies, giving Xtant exclusive U.S. rights to import, market, distribute and sell the FDA-approved HEMOBLAST Bellows hemostatic powder. Xtant also hired about 20 Dilon sales personnel and plans to update its full-year 2026 guidance with its first quarter 2026 results, so shareholders will see the financial effect when that guidance is released.
Xtant paid Dilon a $5.0 million exclusivity fee, which Dilon may have to repay in certain circumstances, including termination of the agreement.
Xtant hired approximately 20 Dilon sales personnel to sell the product in the United States.
Dilon will continue to manufacture HEMOBLAST Bellows in France and sell it to Xtant at a transfer price that can change under the agreement.
The agreement has no minimum purchase requirements for Xtant; Xtant plans to update 2026 guidance with its Q1 2026 results.
Palo Alto Networks signed three lease amendments on April 8, 2026, extending the term of its leases on three Santa Clara, California office buildings for 12 years, from August 1, 2028 to July 31, 2040. The landlord is required to provide a tenant improvement allowance of up to $72.50 per rentable square foot, and base rent is abated for the first 12 months of the extended term.
Extended term runs 12 years, from August 1, 2028 through July 31, 2040
Base rent is $3.825 per rentable square foot per month after the abatement period, with 2% annual increases
Landlord tenant improvement allowance of up to $72.50 per rentable square foot
Nutriband said in a March 30, 2026 press release that it has selected a commercial brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit the name to the FDA for approval. The filing does not report revenue, earnings, or guidance, and the company's $80 million to $200 million peak annual US sales estimate is a potential figure, not a forecast, so the news is a development step toward regulatory review.
Nutriband partnered with Brand Institute, Inc. on the brand name, and its subsidiary Drug Safety Institute will provide regulatory support on the project.
The proposed name and labeling will go to the FDA and other international regulators, and the name is being submitted to the USPTO for trademark registration.
The company says the product has the potential to reach peak annual US sales of $80 million to $200 million, citing a 2022 market analysis report.
Broadcom disclosed agreements with Google to develop and supply custom Tensor Processing Units for future Google TPU generations and to supply networking and other components for Google's next-generation AI racks through 2031. Broadcom, Google and Anthropic also expanded their strategic collaboration, with Anthropic set to access about 3.5 gigawatts of TPU-based AI compute through Broadcom starting in 2027. The filing gives no dollar values, and it notes that Anthropic's consumption depends on its continued commercial success.
Long Term Agreement: Broadcom to develop and supply custom TPUs for Google's future generations of TPUs
Supply Assurance Agreement: networking and other components for Google's next-generation AI racks through 2031
Anthropic to access about 3.5 gigawatts through Broadcom beginning in 2027; parties are in discussions with operational and financial partners
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.